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Abstract: Glutathione (L-γ-glutamyl-L-cysteinyl-glycine; GSH) in cancer cells is 
particularly relevant in the regulation of carcinogenic mechanisms; sensitivity against 
cytotoxic drugs, ionizing radiations, and some cytokines; DNA synthesis; and cell 
proliferation and death. The intracellular thiol redox state (controlled by GSH) is one of the 
endogenous effectors involved in regulating the mitochondrial permeability transition pore 
complex and, in consequence, thiol oxidation can be a causal factor in the mitochondrion-
based mechanism that leads to cell death. Nevertheless GSH depletion is a common feature 
not only of apoptosis but also of other types of cell death. Indeed rates of GSH synthesis 
and fluxes regulate its levels in cellular compartments, and potentially influence switches 
among different mechanisms of death. How changes in gene expression, post-translational 
modifications of proteins, and signaling cascades are implicated will be discussed. 
Furthermore, this review will finally analyze whether GSH depletion may facilitate cancer 
cell death under in vivo conditions, and how this can be applied to cancer therapy. 
Keywords: glutathione; cancer; cell death; apoptosis; necrosis; autophagy 
Abbreviations: GSH: Glutathione; ROS: Reactive oxygen species; TNF: Tumor necrosis 
factor; ARE: Antioxidant response elements; MAPK: Mitogen-activated protein kinase; 
BSO: Buthionine sulfoximine; mtGSH: Mitochondrial GSH; GSSG: Oxidized GSH; 
MRP: Multidrug resistance protein; ABC: ATP-binding cassette; CFTR: Cystic fibrosis 
transmembrane conductance regulator; PKA: Protein kinase A; VRP: Verapamil;  
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Bcl-2-AS: Bcl-2 antisense oligodeoxynucleotides; GGT: γ-glutamyl transpeptidase; ACV: 
Acivicin; GED: L-Gln enriched diet 
 
1. Glutathione in Cancer Biology 
Normal cells respond to external stimuli by different tightly regulated pathways. However, in 
cancer cells, physiology is altered leading to, e.g., excessive growth and reduced cell death. 
Classically, the loss of growth regulation has been attributed to the mutation of oncogenes and tumor 
suppressor genes. Besides, reduction in the response to cell death stimuli is related to aberrant  
anti-death and pro-death protein expression [1].  
Glutathione (GSH, γ-glutamyl-cysteinyl-glycine), is the most abundant non-protein thiol in 
eukaryotic cells. The synthesis of this ubiquitous tripeptide is catalyzed by two cytosolic enzymes:  
γ-glutamate-cysteine ligase (first step), and GSH synthetase (second step; which combines  
γ-glutamyl-cysteine with glycine to generate GSH). Cys availability and γ-glutamate-cysteine ligase 
activity are the rate-limiting factors in GSH synthesis [2]. Owing to its reactivity and high intracellular 
concentrations (approx. 10 mM in the liver and different malignant cells), GSH is involved in cell 
protection against free radicals, and in many cellular functions being particularly relevant in regulating 
carcinogenic mechanisms [3,4]; sensitivity against xenobiotics, ionizing radiation and some  
cytokines [5-11]; DNA synthesis; and cell proliferation [2,12-14] .  
GSH biochemistry deregulation in tumors has been observed in many different murine and human 
cancers [15-17]. In addition to the properties mentioned above, particularly in cancer cells, GSH is 
important in the protection against tumor microenvironment-related aggression [18], apoptosis  
evasion [19], colonizing ability [20], and multidrug and radiation resistance [2,7-9,11,20-23]. 
Increased levels of GSH and resistance to chemotherapeutic agents have been observed, e.g., for 
platinum containing compounds, alkylating agents (such as melphalan), anthracyclines, doxorubicin, 
and arsenic [24].  
Modifications of GSH metabolism and the introduction of agents able to modulate GSH 
concentration in tumor cells opened up the possibility of regulating the cellular response to different 
anticancer treatments [9,10,23,25,26]. Nevertheless, approaches in cancer treatment based on 
modulating GSH levels appear highly limited by potential harmful effects to normal cells. 
2. Redox Control of Cell Death 
In mammals, under physiological conditions, the equilibrium between cell death and division helps 
to maintain tissue/organ homeostasis. Mechanisms related to this equilibrium involve cell cycle 
checkpoints, DNA repair and recombination, and cell death. In all these mechanisms the oxidation and 
reduction of proteins, as well as the rate and nature of free radicals generation, play important roles. 
The term cellular redox state is classically used to describe the balance of NAD
+
/NADH, 
NADP
+
/NADPH, and/or GSH/GSSG, and its relationship to different sets of metabolites and the 
control of cell metabolism [27,28]. 
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Free radicals are defined as molecules or fragments of molecules containing one or more unpaired 
electrons [29,30]. Highly reactive species capable of damaging carbohydrates, lipids, proteins and/or 
nucleic acids, and of causing loss of molecular functions [31]. 
Reactive oxygen species (ROS) represent the more abundant free radicals in mammalian cells [32] 
and include, mainly, superoxide anions (O2
·−
) [33], hydroxyl radicals (
.
OH)[34] and peroxide radicals 
(ROO
.
) [35]. One should also take into account the levels of other molecules, without unpaired 
electrons but also harmful and ROS-related, such as hydrogen peroxide (H2O2) [36]. Besides reactive 
nitrogen species, such as nitric oxide (·NO) [37] and the peroxynitrite (ONOO
−
)[38] also play essential 
regulatory roles. The sources of ROS are the electron transport system in the mitochondria, the Krebs 
cycle, different oxidases (including NADPH oxidase, xanthine oxidase, and certain arachidonic acid 
oxygenase activities) and the radicals released from immune cells [39-42].  
An increase in free radicals levels may lead to an increase in different cellular defense systems or, if 
the damage is irreversible, to cell death [43] (Figure 1). Moreover, oxidative stress or redox status 
shifts may cause cell transition from quiescent to proliferative status, growth arrested or cell death 
activation according to the duration and extent of the redox imbalance [44]. 
Figure 1. Cellular redox balance control regulatory pathways determining cell viability. 
 
Different effectors can lead to redox system oxidations triggering a plethora of cellular responses. If 
stimulation does not compromise cell resistance mechanisms negative feed-back systems restore 
the redox homeostasis and allow cell survival. However, if stimuli cannot be counteracted by the 
antioxidant machinery, redox status alterations cause irreversible loss of cell viability. 
Although several mechanisms of cell death have been characterized, their classification is difficult 
because more than one single mechanism can be activated by the same signal [45]. Main cell death 
mechanisms include: (a) apoptosis, a process of programmed cell death, characterized by cell shrinkage, 
chromatin condensation, caspases activation and DNA fragmentation[46]; (b) necrosis, an uncontrolled 
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event caused by loss of cell homeostasis where cell volume increases[46], and (c) autophagy, where 
degradation of cellular components through the lysosomal machinery is observed [47]. 
Apoptosis can be triggered either through an intrinsic pathway, which involves procaspase-9 
activation downstream of mitochondrial proapoptotic events; or through an extrinsic pathway, 
triggered by membrane receptors [such as Fas ligand or tumor necrosis factor-α (TNF-α)] without 
direct involvement of mitochondria-derived signals [48]. In both cases, the apoptotic machinery 
activates cysteine-aspartate proteases [49].  
Cells possess antioxidant systems to control the redox state and, thereby, survival [43]. Antioxidant 
defenses include superoxide dismutases; catalase; Cys; thioredoxins; peroxiredoxins; sulfiredoxins; 
GSH, and enzymes involved in GSH homeostasis, such as GSH peroxidase, GSH reductase, 
glutaredoxins, and GSH transferases; vitamins; metal-complex proteins, etc. [40,43,50]. In 
consequence, down regulation of these antioxidant defenses can lead to increased ROS levels, redox 
status alterations [19], and cell damage; thus increasing the risk of developing pathologies such as 
cancer, neurodegeneration, etc [19].  
Oxidative stress associates with carbohydrate, lipid, protein and DNA damages, which lead to 
cellular dysfunction and, eventually, cell death[42]. Moreover oxidative stress and/or changes in the 
intracellular redox status may affect nuclear chromatin remodeling (histone acetylation/deacetylation) 
and cause changes in gene expression [51]. Indeed, oxidative stress causes: single- and double-strand 
DNA fragmentation [52]; damages in mitochondria that decrease the transmembrane potential, and 
may associate to permeability alterations and facilitate the release of death-related molecular  
signals [53,54].  
Oxidative stress is a known inducer of the transcription of specific genes involved in cell death [55], 
whereas GSH has been also postulated as potential regulate of gene transcription [56]. Moreover, 
different GSH-related enzyme activities are regulated by a redox-sensitive transcription factor, NF-E2 
p45-related factor-2 (Nrf2) [57]. The oxidation of specific proteins containing thiols induces the 
release of Nrf-2, which then translocates to the nucleus, activating transcriptions through binding to 
antioxidant response elements (ARE) in the control regions of multiple detoxification-related  
genes [58]. Potential redox-sensitive transcription factors, such as Nfr-2, and how they affect gene 
expression represent an open field for research. In fact, several transcription factors are modulated 
through oxidation/reduction of critical Cys localized in their DNA binding domain, essentials for 
recognition of the binding site through electrostatic interactions with specific DNA bases [59]. 
Oxidation of these Cys residues results in changes in the inter- or intramolecular disulfide bonds affecting 
the tridimensional structure of the transcription factor and, in consequence, its function [59,60]. This 
modulation can upregulate or downregulate gene expression, for instance of NF-κB or p53 [50], or 
different receptor tyrosine kinases [phosphokinase C and mitogen-activated protein kinase  
(MAPK)] [19]. MAPKs, such as ERK, p38 and JNK, are central players in the mechanisms of stress 
induced apoptosis [19].  
As well as in transcription factors, changes in the thiol–disulfide status affecting critical Cys in 
enzymes, receptors, or transport proteins, can be reversible or irreversible[19]. Reversible modifications 
of Cys, Met, Trp, and/or Tyr residues (via nitrosylation, hydroxylation, glutathionylation, or disulfide 
bond formation) may differentially affect protein function. Besides, glycerophospholipids and other 
lipids in plasma and organelle membranes are also major targets of oxidizing agents. Lipid  
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oxidation-derived products such as malondialdehyde, 4-hydroperoxy-2-nonenal, 4-o-xo-2-nonenal, or 
4-hydroxy-2-nonenal, can impair membrane functions, inactivate, membrane-bound receptors and 
enzymes, and increase permeability [30,51]. 
In response to stress, the thioredoxin/glutaredoxin complex induces the autophosphorylation and 
activation of apoptosis signal regulating kinase 1 (ASK1), which causes phosphorylation and 
activation of JNK and p38, both involved in apoptosis initiation [61]. 
In case of DNA damage, p53 mediates the response through initiation of DNA repair, cell cycle 
arrest, or activation of an apoptotic signaling cascade. p53 activity is regulated by posttranslational 
modifications, including phosphorylation, acetylation, ubiquitination, sumoylation, glutathionylation, 
cytoplasmic sequestration, etc. [42]. p53 modulates activation of proapoptotic genes, or induces 
apoptosis through transcription-independent mechanisms (e.g., by altering binding actitivities of Bcl-2 
or Bax) [19,42]. 
Finally, it is worthy to remark that some differences among mitochondria, cytoplasm, and nuclei 
can be found. For instance, a possible translocation of GSH into the nucleus in response to acute 
oxidative stress has been suggested [62]. In addition, in mitochondria, complex I glutathionylation 
results in increased superoxide production, then leading to activation of redox signaling pathways 
and/or induction of cell death, depending upon the magnitude of modifications [42]. 
3. Glutathione and the Mechanisms of Cancer Cell Death 
Alterations in cell death mechanisms are common in the pathophysiology of different human 
diseases including cancer, neurodegenerative or autoimmune disorders. The signaling pathways 
leading to cell death, and to programmed cell death type I or apoptosis in particular, have been 
extensively characterized. However, recent studies point out the importance of changes in the 
intracellular milieu affecting apoptosis and other types of cell death. GSH depletion, in particular, is a 
common feature preceding cell demise.  
3.1. GSH Role in Apoptosis 
Although the relationship between GSH and apoptosis is not fully understood, GSH is essential for 
cell survival and its depletion increases the cellular susceptibility to apoptosis [63]. High intracellular 
GSH levels have been related to apoptosis resistance [64,65], and GSH depletion has been shown 
either to induce or potentiate apoptosis [64,66,67]. Buthionine sulfoximine (BSO), a selective inhibitor 
of γ-GCS, induces GSH depletion without triggering apoptosis, but facilitates and potentiates the 
response to other cell death stimulus. For example, BSO potentiates death receptor-induced apoptosis 
in T cells [64,66], and increases the susceptibility to TNF-α treatment in Ehrlich-ascites-tumor-bearing 
mice [14]. Besides, GSH supplementation with GSH ester, or replenishment of GSH pools with  
N-acetyl-L-cysteine or S-adenosyl-methionine (both precursors of Cys), have been shown to be 
effective protectors against apoptosis [65,68,69]. 
The intrinsic apoptotic pathway is mainly activated by ROS, which induces opening of the 
mitochondrial permeability transition pore [70,71], which may cause the release of proapoptotic 
molecules, such as cytochrome c (an intermembrane space protein), to the cytosol. Mitochondrial 
release of cytochrome C is required for the formation of apoptosome and caspase activation, and 
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different death-related signals may cause its release to the cytosol. However, it is important to point 
out that the mitochondrial permeability transition, which may occur either in apoptosis or in necrosis, 
is a sudden increase in the permeability of the inner mitochondrial membrane to solutes with molecular 
masses of up to 1,500 Da. This process is due to opening of a voltage- and Ca
2+
-dependent, 
cyclosporin A-sensitive, high conductance channel called the permeability transition pore [72]. The 
long-standing idea that the permeability transition pore may form at inner-outer membrane contact 
sites and that it may be constituted by the adenine nucleotide translocator in the inner mitochondrial 
membrane and the voltage-dependent anion channel in the outer mitochondrial membrane has not been 
confirmed by genetic ablation of these proteins [73-75]. As of today, however, it is not clear whether 
the outer mitochondrial membrane is necessary for the permeability transition to occur and what 
regulatory properties, if any, it may contribute to the permeability transition pore. Among the variety 
of effectors that regulate the permeability transition pore open-closed transitions, oxidizing agents have 
received considerable attention, and changes in the redox state of pyridine nucleotides, GSH, and 
sulfhydryl groups have been shown to play a prominent regulatory role [76-81].  
Apoptosome complexation, results in activation of caspase-9, which in turn activates effector 
caspases to carry out the process of apoptosis [40,82]. Opening of the mitochondrial permeability 
transition pore is facilitated by direct depletion of the mitochondrial GSH (mtGSH), even in the 
absence of high (non-physiological) ROS levels [83]. This fact indicates a direct regulatory role of 
mtGSH in regulating the first step in the mitochondria-dependent apoptotic cascade. 
Furthermore, cellular GSH depletion induced by either abolishment of the γ-glutamate-cysteine 
ligase activity in knock-out mice, Cys starvation, or knockdown of γ-glutamate-cysteine ligase in 
culture cells, induces apoptosis [84,85]. In this sense it appears interesting to consider GSH depletion 
as a cellular event preceding (or required for) apoptosis. GSH depletion is in fact an early hallmark in 
the progression of programmed cell death in response to apoptotic stimuli [86,87]. Indeed GSH 
depletion has been classically associated to, e.g., a primary increment in ROS production, although 
GSH depletion may also be dependent on GSH extrusion [88]. Interestingly it has been shown that 
resveratrol, a plant-fruit-derived polyphenol capable of inducing apoptosis in different experimental 
models, activates GSH efflux [83]. For instance, GSH efflux-induced intracellular GSH depletion leads 
to a BAX overexpression-mediated apoptosis activation in lung cancer cells (a ROS-independent 
mechanism) [83,89,90]. 
On the other hand, GSH synthesis is upregulated during oxidative stress and inflammation. In 
practice, oxidants such as ozone, hyperoxia, H2O2, etc. cause short-term falls in intracellular GSH 
which associate with higher oxidized glutathione (GSSG) levels; this is followed by increases in GSH 
levels and/or upregulation of γ-glutamate-cysteine ligase mRNA in in vivo and in vitro models [91-93]. 
Therefore, oxidants and oxidant-generating systems (if their levels do not compromise cell viability) 
can upregulate GSH synthesis-linked genes, thus providing paradoxically a protective mechanism 
against oxidative stress.  
Different studies have been tried to elucidate the molecular mechanisms implicated in GSH 
synthesis regulation [25,57,58,68]. The γ-glutamate-cysteine ligase promoter contains potential  
cis-acting elements, including consensus recognition sites for binding of different transcription factors 
such as: activator protein-1 and -2 (AP-1 and AP-2), Sp-1, NF-kB, and electrophile responsive element 
(ARE) containing an embedded phorbol myristate acetate-responsive element (TRE/AP-1) [94]. These 
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factors are active in response to diverse stimuli and all of them affect the γ-glutamate-cysteine ligase 
subunit genes. For example, β-naphtoflavone, a planar aromatic xenobiotic, modulates γ-glutamate-
cysteine ligase in the liver cell line HepG2 through TRE/AP1 and ARE [95]; in addition, it has been 
shown that H2O2-dependent activation of GCL-ARE4 reporter occurs via MAPK pathways without 
oxidation of cellular GSH or the redox protein thioredoxin-1, thus suggesting that cell GSH/GSSG 
redox status is not required for regulation of γ-glutamate-cysteine ligase or ARE [96]. Furthermore, 
antioxidants trigger protection against oxidants either by directly scavenging these molecules or by 
regulating intracellular GSH levels through the induction of γ-glutamate-cysteine ligase [94]. In fact 
many antioxidants can exert direct effects upon several signal transduction enzymes independently of 
their antioxidant function [97]. 
Nrf-2 is a transcription factor essential in HepG2 cells for the ARE-mediated induction of phase II 
detoxifying and γ-glutamate-cysteine ligase genes in response to ROS, electrophiles and phenolic 
oxidants [98]. Mice deficient in Nrf-2 (Nrf-2
−/−
) have shown an increased susceptibility to the injurious 
effects of hyperoxia, as noted by a marked increase in pulmonary permeability, macrophage 
inflammation, and epithelial injury as compared to control wild mice [99]. Moreover, reduction in 
ARE expression and in different redox balance-related enzymes in lung was observed in Nrf-2 
−/−
 mice 
versus normal mice. In these effects, Nrf-2 participates by directly regulating γ-glutamate-cysteine 
ligase genes and GSH-dependent enzymes expression [98,100]. Interestingly, Nrf-2 levels have been 
shown directly associated with resistance to apoptosis [101].  
Furthermore, Kelch-like ECH associated protein 1 (Keap-1) plays a critical role in ARE-mediated 
signaling by down regulating Nrf-2. Keap-1 inhibits Nrf-2 action by binding and retention of the 
transcription factor in the cytoplasm [102]. Under ROS or electrophilic insults the complex is 
dissociated and Nrf-2 is translocated to the nuclei where transactivates target genes [94,103]. 
Nrf-2 expression is also regulated by GSH [94]. Murine embryonic fibroblast survived in the 
presence of BSO, even though most intracellular GSH was depleted [104], which associated to 
activated Nrf-2 and up-regulation of antioxidant enzymes. Nrf-2-deficient murine embryonic 
fibroblasts lost this capacity and ROS accumulation, caspase-3 activation and cell death were 
promoted. Furthermore, Nrf-2 deficient cells were more susceptible to doxorubicin and BSO 
treatment-induced cell death than wild cells [94]. Moreover, propyl gallate activated caspases 3, 8,  
and 9, and induced an increase in p53, Bax, Fas, and Fas Ligand; whereas MAPKs inhibited nuclear 
translocation of Nrf-2 and induced intracellular GSH depletion in human leukemia [105]. These results 
showed that an early event of propyl gallate-induced apoptosis is MAPKs/Nrf-2-mediated GSH 
depletion, thus indicating that Nrf-2 is one of the first factors that induce cell survival under GSH 
depletion, which points out to this transcription factor as an attractive target in leukemia but also in 
other cancers sharing similar molecular mechanisms. 
The induction of apoptosis through ASK1, under ROS stimulation, is dependent of cellular redox 
status. Treatment of A549, an established cellular line from human lung adenocarcinoma, with 
denbinobin induced ROS production and JNK activation with downstream Bim expression. Bim 
knockdown by siRNA, and N-acetyl-L-cysteine or GSH treatment, reduced denbinobin-induced A549 
cell apoptosis [106]. In the same way, treatment of hepatoma cells with aloe-emodin, a bioactive 
anthraquinone of Rheum palmatum with anticancer properties, induced oxidative stress and apoptosis 
in a mechanism mediated by ASK1 and JNK activation. Furthermore, inhibition of GSH synthesis by 
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BSO, or treatment with glutathione monomethyl ester as a GSH donor, sensitized or protected 
hepatoma cells to JNK activation. Thus indicating a critical role of oxidative stress and sustained JNK 
activation in aloe-emodin-mediated apoptotic cell death in human hepatoma cells [107]. On one hand, 
ASK1 is one of the main activators of apoptosis under oxidative stimuli; whereas on the other hand its 
activity depends on GSH levels. Therefore modulation GSH levels could be critical to increase the 
susceptibility of cancer cells to different antitumoral treatments. 
3.2. GSH Role in Autophagy and Necrosis and the Links between Different Types of Cell Death 
Autophagy or programmed cell death type II consists of the selective degradation of cellular 
components through the lysosomal machinery [47]. This is the major catabolic pathway by which cells 
degrade and recycle macromolecules and organelles. Autophagy can be activated by different stimuli 
such as amino acid deprivation, ROS, cancer, pathogen infections, etc. [108]. Initially cells use 
autophagy as a mechanism to preserve their viability. However, if cells cross a critical threshold, 
macromolecular destruction causes cell death [108]. Autophagy is initiated by the surrounding of 
cytosolic constituents, macromolecules or organelle, in a closed double membrane structure called 
autophagosome. Autophagosome fuses with lysosomes to form autolysosomes. The lysosomal 
hydrolases digest the vesicle content [108]. When stimuli are too high or prolonged, autophagy 
becomes a prodeath mechanism. Specific morphological changes observed in autophagic cells include 
a massive vacuolization of the cytoplasm in the absence of chromatin condensation [109]. The role of 
GSH in autophagy is not fully understood but replenishment of GSH level using N-acetyl-L-cysteine 
prevents autophagy induction and autophagosome formation and protein degradation induced by 
starvation [110,111]. Lipopolysacharide induces autophagy in a GSH-dependent manner since it is 
able to increase ROS production and deplete the tripeptide levels [112]. Nitric oxide produces 
nitrosative and oxidative stress and cellular damage, which induces autophagic cell death in GSH 
depleted osteoblasts [112-114]. 
Classically cellular necrosis refers to a cell that, in response to severe physical or chemical damage 
or a critical decrease in energy availability, swells and explodes, then releases its intracellular content 
into the surrounding space. Thus, necrosis has been considered an uncontrolled type of cell death [112]. 
However, there are recent studies suggesting that necrosis is a regulated process involved in multiple 
development, pathological and physiological scenarios [112]. Inhibition of cellular energy production, 
generation of ROS, imbalance of cellular Ca
2+
 homeostasis or extracellular cell death signals, are 
among those stimuli able to induce either apoptosis or necrosis [115]; thus showing that different types 
of cell death can share, at least in part, common mechanisms. In this sense, time and intensity of 
stimulus may determine the type of cell death. In fact, depending on GSH depletion and oxidative 
stress level apoptosis can switch to necrosis [72]. For instance, the sensitivity of Ehrlich ascites tumor 
cells to TNF-α depends on their GSH content and their rate of proliferation. This is important because 
tumor cell populations under active proliferative states may show higher GSH levels, and drug- and/or 
radiation-resistant tumors have increased cellular levels of GSH. In fact, TNF-α induces a shift towards 
oxidation in the mtGSH status, a fact that is consistent with the hypothesis that mtGSH plays a key 
role in scavenging TNF-α-induced ROS [116]. 
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4. Glutathione Depletion and Cancer Therapy  
4.1. Potential Benefits and Limitations 
The fact that GSH depletion can be deleterious for cancer cells and, potentially, enhance the 
effectiveness of chemotherapy and/or ionizing radiations, is known [7,25,56]. The value of GSH 
depletion in sensitizing tumor cells to ionizing radiation was first demonstrated in several human 
lymphoid cell lines [117]. Indeed, as reviewed later, cancer cells containing low GSH levels (<10% of 
their control values) were found much more sensitive than control cells to the effects of γ-irradiation [2]. 
GSH and drug resistance of cancer cells have been also linked [25,118]. Chemoresistance is a 
multifactorial phenomenon and many studies show that a coordinated expression of efflux transporter 
proteins and phase II conjugating enzymes in tumor cells is linked to the development of the multidrug 
resistance phenotype. In particular, the overexpression of GSH transferase and efflux pumps in tumors 
may reduce the reactivity of various anticancer drugs. 
The relationship between GSH depletion, chemotherapy, and/or the radiation response has been 
examined in many tumor cells after treatment with different drugs, including BSO, diethylmaleate,  
2-oxothiazolidine-4-carboxylate, and different radiosensitizing agents [2,8,25,119,120]. However BSO 
(as well as other thiol-depleting agents) is non-specific and, besides promoting tumor GSH depletion 
in vivo, can cause irreversible damage in most normal tissues. Moreover, GSH depletion only appears 
to be therapeutically effective when very low levels of this tripeptide can be achieved within the cancer 
cells [25]. Thus, achievement of selective tumor GSH depletion under in vivo conditions appears as a 
superb pharmacological challenge.  
In fact, since the molecular background was firmly established, the potential benefits of GSH 
depletion for cancer therapy have remained in the shadow for two decades. Nevertheless, recently, new 
research has offered some light on how to make GSH depletion a useful tool in cancer therapy.  
4.2. Molecular Mechanisms Channeling Cytosolic GSH Efflux 
Drug resistance frequently associates with over-expression of P-glycoprotein and/or multidrug 
resistance proteins (MRPs), which work as pumps extruding cytotoxic drugs out of the tumor  
cells [24,121-123]. Efflux of GSH, GSSG, and GSH S-conjugates (xenobiotics or metabolites) from 
different mammalian cells appears channeled through different MRPs [24,25,124-127]. Potential 
endogenous substrates for MRPs have been recently revised by Ballatory et al. (2009) [126,128].  
A total of nine multifunctional mrp genes have been identified (from mrp1 to mrp9). But MRP-1, 
MRP-2 and MRP-4 are principally responsible for the transport of GSH [127,129,130], whereas the 
others MRPs have different substrates (e.g., bilirubin glucuronosides for MRP2 and MRP3, or cyclic 
AMP and cyclic GMP for MRP4, MRP5, and MRP8) [130]. Activation of Nrf2-Keap1 pathway 
stimulates the induction of MRPs expression, as well as genes responsible for both the synthesis and 
conjugation of GSH [129,131,132]. 
MRP1, the first to be cloned, is overexpressed in many drug-resistant cancer cells and functions as a 
drug efflux pump [127]. Its expression is much lower in most normal tissues where it works to 
decrease accumulation of xenobiotics and their metabolites [127,133]. MRP1 mediates the  
ATP-dependent transport of different organic (including naturally occurring conjugated metabolites 
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and most GSH-, glucuronide-, and sulfate-conjugated products of phase II xenobiotic metabolism) and 
inorganic anions (e.g., antimonial and arsenical oxyanions) [133]. MRP1 may even act in cooperation 
with GSH transferases (e.g., GSTP1) to protect cancer cells from cytotoxic drugs [134].  
GSH depletion by BSO-induced inhibition of γ-glutamate-cysteine ligase [26] resulted in a 
complete reversal of resistance to anticancer drugs of different cell lines overexpressing MRP1 but had 
no effect on P-glycoprotein-mediated multidrug resistance [135]. Cancer cells may release GSH 
through MRP1 even in the absence of cytotoxic drugs [124]. In addition GSH is required for the 
transport by MRP1 of GSH conjugates of, e.g., vincristine or doxorubicin, but is also evident that in 
some cases (e.g., vinca alkaloids) drugs are co-transported with GSH [127]. This requirement for GSH 
may explain why drug extrusion through MRP1 decreases in BSO-treated cells, thus indicating that 
MRP1 also transports non-conjugated GSH [136,137]. MRP1-channelled GSH export from cells can 
be also increased by different xenobiotics, including arsenite, verapamil (VRP), and some  
naturally-occurring flavonoids [138,139], although for these molecules there is no evidence that their 
MRP1-mediated transport could be stimulated by GSH. On the other hand, there is reciprocal 
cooperativity between GSH and, e.g., vincristine in their MRP1-mediated co-transport [140]. 
Moreover GSH increases: (a) the inhitory effect of, e.g., flavonoids and vinca alkaloids on the  
MRP1-mediated transport of organic anions; whereas (b) stimulates the transport of different 
glucuronate, sulfate and GSH conjugates [127]. Nevertheless, it remains undefined what exactly 
determines the GSH requirement for the transport of a particular substrate, although it appears 
plausible that MRP1 may have several drug-binding sites. 
We have presented evidence showing that GSH is released from highly metastatic B16-F10 melanoma 
cells through MRP1 and the cystic fibrosis transmembrane conductance regulator (CFTR) [141]. The 
CFTR, a member of the ABC family of membrane transport proteins with structural similarities with 
MRP1, forms a phosphorylation- and ATP-dependent channel permeable to Cl
−
 and to other larger 
organic anions, including GSH [142]. The CFTR, which is expressed in different cell types, is 
activated by the binding of ATP to its cytoplasmic nucleotide-binding domain and by phosphorylation 
of key Ser residues in the regulatory domain [143]. Phosphorylation is mediated principally by  
cAMP-dependent PKA and by phosphokinase C (although to a lesser degree than the activation by 
PKA) [144]. Basal expression of the CFTR gene is dependent on PKA activity [145]. Treatment of 
human colon carcinoma T84 cells with the PKA-selective inhibitor N-[2-(p-bromocinnamylamine) 
ethyl]-5-isoquinolinesulfonamide (H-89) causes a complete suppression of CFTR gene expression 
without affecting other constitutively active genes [145]. Addition of anti-CFTR antibodies to MRP
−/−
1 
(MRP 1 knockout) B16-F10 cells practically abolished GSH efflux from B16-F10 cells [141]. This 
indicating the existence of different molecular channels controlling the rate of GSH efflux from B16-
F10 cells: MRP1, and the Bcl-2-dependent CFTR transporter [25]. Nevertheless, the possibility cannot 
be ruled out that other mechanism(s) may also be working in other cell types or that different CFTR 
gene mutations could be found when comparing different cancer cells. Although what appears really 
relevant is the fact that the rate of efflux may become an important factor regulating intracellular GSH 
content and, thereby, cancer cell survival and resistance to treatments. 
We showed that Bcl-2 antisense oligodeoxynucleotides (Bcl-2-AS; which prevent the Bcl-2-dependent 
inhibition of GSH efflux through CFTR) and VRP (which increases the MRP1-dependent GSH efflux) 
independently increased rates of GSH efflux from perifused B16M-F10 cells [141]. The perifusion 
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technique through a chamber, where isolated cancer cells are maintained in suspension at 37 °C, 
represents an experimental setup that mimics in vivo conditions by providing a constant supply of 
glucose, amino acids, oxygen, CO2 and GSH at physiological plasma concentrations. This setup 
allowed us to use a VRP concentration (1 μM) that corresponds to clinically accepted and nontoxic 
levels in plasma [141]. Intracellular GSH content was significantly decreased (∼30%), as compared to 
controls, in Bcl-2-AS- and VRP-treated B16M-F10 cells after 6 h of perifusion. However, at 12 h of 
perifusion, GSH levels were ∼70% higher in Bcl-2-AS- and VRP-treated B16M-F10 cells than in 
controls [141] Thus, it appears that loss of GSH accelerates their rate of intracellular synthesis. In fact, 
we found that increased GSH efflux was associated with γ-glutamate-cysteine ligase overexpression [141]. 
In growing tumors, cyst(e)ine, whose concentration in blood is low, may become rate-limiting for 
GSH synthesis and cell growth [17,146]. Cystine is predominant outside the cell since Cys rapidly 
autoxidizes to cystine in the extracellular fluids, whereas once it enters the cell through the Xc
−
 
system, cystine is reduced to Cys and used preferentially for protein and GSH synthesis [147]. 
Tumor γ-glutamyl transpeptidase (GGT) activity (frequently overexpressed in many tumors [148]) 
can cleave extracellular GSH (the liver being the main exporter), releasing γ -glutamyl-aminoacids and 
cysteinylglycine, which is further cleaved by membrane-bound dipeptidases into Cys and Gly [26]. 
Free γ-glutamyl-amino acids, Cys, and Gly entering the cell serve as GSH precursors [26].  
Therefore, GGT may provide tumor cells with a growth advantage at physiological concentrations of 
cyst(e)ine [17,146]. 
Therefore, if the increase in GSH content, which follows the effect of Bcl-2-AS and VRP on GSH 
efflux, depends on cyst(e)ine availability, and if this is provided in part by GGT, then inhibition of the 
activity of this enzyme could limit GSH synthesis. This possibility was tested by adding acivicin 
(ACV), an irreversible GGT inhibitor [149], to the B16 perifusion system. ACV decreased GGT 
activity to non-detectable levels and decreased GSH synthesis but without affecting the rate of GSH 
efflux or the rate of cystine uptake [141]. Hence, Cys availability within malignant B16M cells 
appears, indeed, to be modulated by its GGT-dependent generation from extracellular GSH. In 
consequence, we concluded that Bcl-2-AS- and VRP-induced acceleration of GSH efflux, combined 
with inhibition of GGT, could represent a useful methodology to deplete GSH in B16-F10 cells in vivo. 
Importantly this approach appeared selective since it did not decrease GSH in normal tissues [17]. 
4.3. Mitochondrial GSH and the Glutamine Trap  
Mitochondrial dysfunction is a common event in the mechanisms leading to cell death [150]. 
Mitochondrial permeability transition is critical in the process leading to apoptosis, and it is linked to 
the opening of a permeability transition pore complex [150] (see also above). This molecular gate is 
regulated by many endogenous factors, including divalent cations (e.g., Ca
2+
 and Mg
2+
), protons, the 
concentration of adenine nucleotides, the thiol (controlled by GSH) and the pyrimidine redox state, the 
rate of ROS and reactive nitrogen species generation, the concentration of lipoids (e.g., ceramide), the 
concentration of certain peptides targeting proteins for mitochondrial import, and the function of 
different pro- and anti-apoptotic proteins [151].  
GSH, which is not synthesized by mitochondria but taken up from the cytosol through a 
multicomponent transport system [2,86], is involved in the defense against peroxides generated from 
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the electron transport chain [152] and is an important regulator of the mitochondrial permeability 
transition and permeability transition pore opening [11,25,150,151]. Thus, impairment of GSH uptake 
by mitochondria (or direct mtGSH depletion) appears a useful mechanism to sensitize malignant cells 
to molecular effectors (e.g., oxidative stress inducers and/or cytotoxic drugs) capable of activating the 
mitochondrion-based death mechanism. Naturally, to be really effective under in vivo conditions, such 
an approach should be totally (or at least partially) selective for the cancer cells and therefore not affect 
normal cells. 
Tumor cells need a constant supply of both energy and nitrogen substrates. Having originated from 
Warburg's [153] seminal observation of aerobic glycolysis in tumor cells, most of this attention has 
focused on glucose metabolism. However, since the 1950s cancer biologists have also recognized the 
importance of L-Gln, the most abundant amino acid in blood, as a tumor nutrient [154]. L-Gln, which 
accounts for 50% of the whole body pool of free amino acids, contributes to essentially every core 
metabolic task of proliferating tumor cells: it participates in bioenergetics, supports cell defenses against 
oxidative stress and complements glucose metabolism in the production of macromolecules [155]. 
Indeed, many tumors and rapidly dividing cells exhibit a remarkable preference for L-Gln as 
respiratory fuel [156]. In many cancer cells, L-Gln is the primary mitochondrial substrate and is 
required for maintenance of mitochondrial membrane potential and integrity and for support of the 
NADPH production needed for redox control and macromolecular synthesis [157]. A host to tumor net 
flux of L-Gln in mice bearing Ehrlich tumors has been described [158], and studies in different tumors 
have demonstrated that L-Gln utilization correlates with: (a) increased mitochondrial phosphate-dependent 
glutaminase activity that is dependent on Rho GTPases and NF-kB activity [155,156,159];  
and (b) oncogenic levels of Myc which induce a transcriptional program that promotes glutaminolysis 
and trigger cellular addiction to L-Gln as a bioenergetic substrate [160]. Tumors with high rates of 
glutamine uptake and metabolism can behave as glutamine traps, depleting host glutamine stores, 
producing glutamate rapidly, and resulting in cachexia [156,161]. However, we recently suggested that 
these peculiarities could represent an advantage in terms of developing a novel strategy to treat cancer.  
Providing supplemental L-Gln during cancer treatment, by reducing the incidence of gastrointestinal, 
neurological and possibly cardiac complications, has the potential to minimize chemotherapy- and/or 
radiation-related toxicity [162-166]. L-Gln, preferentially formed and stored in skeletal muscle, is the 
principal metabolic fuel for small intestine enterocytes, lymphocytes, macrophages, and fibroblasts [167]. 
L-Gln-enriched diets (GED) may support muscle L-Gln metabolism without stimulating tumor  
growth [159,162-167]. Moreover, a high rate of L-Gln oxidation may render the mitochondria more 
susceptible to ROS-mediated cytotoxicity by TNF-α [11,168]. In previous studies in Ehrlich ascites 
and highly metastatic B16-F10 melanoma tumor cells, we found that L-Glu derived from L-Gln 
competitively inhibited GSH transport into mitochondria [159,169], thereby depleting selectively 
tumor mtGSH under in vivo conditions [159] and rendering tumor cells more susceptible to oxidative 
stress-induced mediators, such as TNF-α [11].  
We developed an original methodology to produce L-Gln-adapted malignant cells with very high 
metastatic potential (B16M-F10-Gln
+
). These cells grew as a local tumor in the footpad of mice fed a 
GED which, as compared with control tumor-bearing mice fed an standard diet, did not accelerate 
cancer growth [169]. Moreover, the GED significantly decreased the loss of body weight and the 
release of skeletal muscle L-Gln [169], which suggests anticachectic properties. Indeed, in randomized, 
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double-blind controlled clinical trials, cancer patients receiving L-Gln-supplemented parenteral nutrition 
had improved nitrogen balance, a diminished incidence of clinical infections and less extracellular 
fluid accumulation, clinical facts that are consistent with the potential role of L-Gln in stimulating 
protein synthesis in skeletal muscle, supporting endothelial function and integrity, and enhancing 
immune functions (see [169] and references therein for a review). Furthermore, in rats, provision of a 
GED during whole abdominal irradiation (10 Gy, a dose that results in a 50% mortality rate in a few 
days) exerted a protective effect on the small bowel mucosa by supporting crypt cell proliferation and, 
thereby, accelerated healing of the irradiated bowel and reached a 100% survival of the irradiated 
animals [162,164]. Besides, L-Gln supplementation may also decrease the incidence and/or severity of 
chemotherapy-associated mucositis, irinotecan-associated diarrhea, paclitaxel-induced neuropathy, 
hepatic veno-occlusive disease in the setting of high dose chemotherapy and stem cell transplantation, 
and the cardiotoxicity that accompanies anthracycline use [164]. Studies in patients receiving L-Gln-
enriched nutrition for several weeks confirmed the clinical safety of this approach in a catabolic patient 
population [163]. Therefore, supplementation of a GED appears a feasible methodology to deplete 
mtGSH levels [10,25,159,169] in growing malignant cells, and in addition may promote beneficial 
effects for the cancer patient. 
5. GSH Depletion: A Feasible Strategy to Improve Cancer Therapy  
As explained above, GSH efflux activation through MRP1 and a putative GSH transporter of an 
undefined molecular nature that was found to correspond to CFTR in B16 melanoma cells, limitation 
of Cys supply for de novo synthesis of GSH, and glutamate (Gln-derived)-induced competitive 
inhibition of cytosolic GSH transport into mitochondria, can promote both cytosolic and mitochondrial 
GSH depletion in the tumor cells. This strategy, which preferentially affects tumor and not normal 
cells, causes a decrease in tumor cell defenses and resistance to oxidative stress inducers (such as TNF-α 
or ionizing radiations) and cytotoxic drugs [10,11,17,25,141,159,169]. Figure 2 schematically summarizes 
the molecular interrelationships leading to depletion of the cytosolic and mitochondrial pools.  
Nevertheless, it is essential to keep in mind that in vivo growing tumors represent a heterogeneous 
tissue, with different cell types (cancer, blood and lymphatic vessels, fibroblasts, immune cells, etc.) 
and tissue-specific microenvironments. In addition, tumor cells are also heterogeneous and may 
contain several cell subsets with different levels of resistance to death-inducing stimuli. Regarding 
GSH, its content within the cancer cell may vary depending on the rate of cell growth. In addition, we 
cannot rule out the possibility that mechanisms channeling GSH efflux differ when comparing 
different cancer types, or that, e.g., different CFTR gene mutations, could be found when comparing 
different cancer cells. 
What is then the good news? This approach is the first to achieve selective GSH depletion in 
different cancer cell types growing in vivo. Drugs used all function at clinically acceptable doses.  
VRP (activating GSH efflux through MRP1), is a calcium ion influx inhibitor frequently used for 
the management of hypertension and angina pectoris, which has also been used in patients receiving 
chemotherapy for example, myeloma or acute lymphocytic leukemia. Cells isolated from these patients 
showed increased accumulation of daunorubicin or vincristine [170] when patient plasma 
concentrations of VRP were similar to murine VRP plasma levels in our experiments [141]. 
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Figure 2. Experimental therapy to deplete GSH levels in cancer cells. 
 
Increased cytosolic GSH efflux, Cys shortage-induced decrease in GSH synthesis and inhibition of 
GSH transport into mitochondria, lead to cytosolic and mitochondrial GSH depletion, thus 
sensitizing tumor cells to chemo- and radiotherapy. Cytosolic GSH efflux is stimulated by 
verapamil and Bcl-2 antisense oligodeoxynucleotides treatment. Acivicin-induced -GT inhibition 
limits Cys availability for GSH synthesis. L-Glu is a competetive inhibitor of GSH transport into 
mitochondria. High levels of cytosolic L-Glu are achieved by a glutamine-enriched diet which 
promotes a higher mitochondrial glutaminase activity. This strategy may render cancer cells (and 
abnormal cells) more sensitive to oxidative stress inducers and cytotoxic drugs. 
ACV (a GGT inhibitor) has been evaluated for antitumor activity in phases I and II clinical trials 
because expression of GGT was observed in melanoma and cancers of the liver, lung, breast, and 
ovary [148,171]. These trials revealed central nervous system toxicities, so a maximum dose of 50 mg 
ACV/m
2
/day in combination with the amino acid solution aminosyn to reduce ACV uptake in the 
central nervous system was proposed. However, the application of ACV described here is not 
predicted to require aminosyn. The pharmacokinetic parameters of ACV in patients [171], our efficacy 
results, and previous preclinical studies [141] all suggest that ACV plasma levels sufficient to block 
GGT activity in tumors would be below the levels that resulted in central nervous system toxicity. 
Bcl-2-AS therapy has been evaluated in multiple clinical trials [172-174]. Bcl-2-AS therapy using 
G3139, for example, an 18-base phosphorothioate oligonucleotide complementary to the first six 
codons of the Bcl-2 mRNA, selectively and specifically inhibits Bcl-2 expression and promotes 
apoptosis in different human and murine cancer cell lines [175]. G3139 is well tolerated at doses 
comparable to that used in our studies (e.g., [176] and references therein). Systemic administration of 
G3139 to Shionogi tumor-bearing mice led to a rapid decrease of tumor size (higher when chemotherapy 
was simultaneously administered), whereas the oligonucleotide did not affect Bcl-2 expression in 
normal organs [177,178]. G3139-induced tumor regression without dose-limiting toxicity was also 
observed in other tumors, melanoma, lymphoma, or gastric cancers for example [175]. Furthermore, 
synergism of the G3139 and anticancer drugs was also shown in different tumors [172,179-182]. 
Cancers 2011, 3                            
 
 
1299 
GEDs are used clinically (see above) and, thus, tumor cell adaptation to a GED (as a previous step 
before cytotoxic/target therapies are applied) is feasible. 
Therefore the proposed strategy (or variations of it) can easily be applied and may represent a 
significant improvement in the therapy of different cancers. With this aim, further experimental work 
and clinical trials, combining GSH depletion with current cancer therapy protocols, are necessary 
steps forward. 
6. Conclusions 
GSH participates in cancer cell protection against xenobiotics, ionizing radiations, and oxidative 
stress-inducing biotherapy. In addition mitochondrial GSH oxidation, in particular, favors opening of 
the mitochondrial permeability transition pore complex, thus facilitating the release of death-related 
molecular signals. Moreover, GSH is also involved in regulating other types of cancer cell death, 
including necrosis and autophagy.Identification of the mechanisms controlling GSH homeostasis and 
fluxes in cancer cells allowed to elucidate a potential, GSH-depletion-based, strategy to improve the 
efficacy of cancer therapy. This involves (a) cytosolic GSH depletionthrough an increase of GSH 
efflux out of cells; and (b) mitochondrial GSH depletion through inhibition of its transport into these 
organelles. Nevertheless these mechanisms need to be assayed in different tumor types in order to 
make this strategy as general as possible. 
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